© Monkey Business/Fotolia
© Monkey Business/Fotolia

Thermo Fisher Scientific and Samsung Electronics will jointly design, develop, and market new point-of-care (POC) solutions in key applications, such as the detection of sepsis, drugs of abuse, and therapeutic drug monitoring as well as the detection of cardiac problems and women’s health conditions.

“Samsung has developed a compelling and innovative suite of POC platforms,” said Marc Tremblay, Ph.D., president of Thermo Fisher’s clinical diagnostics business. “We look forward to working with Samsung to add some of our leading biomarkers and assays to their platforms to create a truly differentiated testing menu.”

“We are very excited to leverage Thermo Fisher Scientific’s strong commercial sales and service channels, as well as the potential to offer a broader range of tests to our customers and their patients,” said Soo-In Cho, president and head of the health and medical equipment business at Samsung. “This strategic collaboration combines the strengths of two industry leaders to accelerate POC innovation and more rapidly bring solutions to market.”

This year, Thermo has affirmed its personalized medicine ambitions. In September, the company entered an agreement with GlaxoSmithKline and Pfizer to develop a universal next-generation sequencing oncology test for solid tumors that will serve as a companion diagnostic for multiple drug programs. 

Also of Interest